EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma

Ekaterina Minskaia, Jesmeen Maimaris, Persephone Jenkins, Adriana S Albuquerque, Ying Hong, Despina Eleftheriou, Kimberly C Gilmour, Richard Grace, Fernando Moreira, Bodo Grimbacher, NIHR Bioresource-Rare Diseases Consortium, Emma C Morris und 1 weitere

Journal of Clinical Immunology · 2023-10 · 43 (7) · 1611-1622

DOI: 10.1007/s10875-023-01530-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 14.06.2023. Verfasst von Ekaterina Minskaia und 12 weiteren Autor:innen. Beteiligte Einrichtung: University College London Institute of Immunity and Transplantation, London, UK. Hauptthemen laut MEDLINE: Interleukin-4, Lymphoma, Follicular. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Versus Arthritis, Department of Health, University College London Hospitals Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transcription factor STAT6 (Signal Transducer and Activator of Transcription 6) is a key regulator of Th2 (T-helper 2) mediated allergic inflammation via the IL-4 (interleukin-4) JAK (Janus kinase)/STAT signalling pathway. We identified a novel heterozygous germline mutation STAT6 c.1255G > C, p.D419H leading to overactivity of IL-4 JAK/STAT signalling pathway, in a kindred affected by early-onset atopic dermatitis, food allergy, eosinophilic asthma, anaphylaxis and follicular lymphoma. STAT6 D419H expression and functional activity were compared with wild type STAT6 in transduced HEK293T cells and to healthy control primary skin fibroblasts and peripheral blood mononuclear cells (PBMC). We observed consistently higher STAT6 levels at baseline and higher STAT6 and phosphorylated STAT6 following IL-4 stimulation in D419H cell lines and primary cells compared to wild type controls. The pSTAT6/STAT6 ratios were unchanged between D419H and control cells suggesting that elevated pSTAT6 levels resulted from higher total basal STAT6 expression. The selective JAK1/JAK2 inhibitor ruxolitinib reduced pSTAT6 levels in D419H HEK293T cells and patient PBMC. Nuclear staining demonstrated increased STAT6 in patient fibroblasts at baseline and both STAT6 and pSTAT6 after IL-4 stimulation. We also observed higher transcriptional upregulation of downstream genes ( XBP1 and EPAS1 ) in patient PBMC. Our study confirms STAT6 gain of function (GOF) as a novel monogenetic cause of early onset atopic disease. The clinical association of lymphoma in our kindred, along with previous data linking somatic STAT6 D419H mutations to follicular lymphoma suggest that patients with STAT6 GOF disease may be at higher risk of lymphomagenesis. 245 words.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-4Lymphoma, FollicularHumansLeukocytes, MononuclearSTAT6 Transcription FactorGain of Function MutationHEK293 CellsJanus Kinases

Stichwörter der Autor:innen

AtopyGain-of-functionLymphomaSTAT6

Substanzen

Interleukin-4STAT6 Transcription FactorJanus KinasesSTAT6 protein, human

Autor:innen und Institutionen

  • University College London Institute of Immunity and Transplantation, London, UK.
  • University College London Institute of Immunity and Transplantation, London, UK. j.maimaris@ucl.ac.uk.
  • Department of Immunology, Royal Free London NHS Foundation Trust, London, UK. j.maimaris@ucl.ac.uk.
  • Inflammation and Rheumatology Section, University College London Institute of Child Health, London, UK.
  • Rheumatology Department, Great Ormond Street Hospital National Health Service (NHS) Foundation Trust, London, UK.
  • Clinical Immunology Laboratory, Great Ormond Street Hospital of Children NHS Foundation Trust and NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK.

Förderung

  • Versus Arthritis
  • Department of Health
  • University College London Hospitals Biomedical Research Centre
  • UCLH Biomedical Research Centre

Zitieren

APA

Minskaia, E., Maimaris, J., Jenkins, P., Albuquerque, A. S., Hong, Y., Eleftheriou, D., Gilmour, K. C., Grace, R., Moreira, F., Grimbacher, B., NIHR Bioresource-Rare Diseases Consortium, Morris, E. C., & Burns, S. O. (2023). Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma. Journal of Clinical Immunology, 43(7), 1611-1622. https://doi.org/10.1007/s10875-023-01530-7

Vancouver

Minskaia E, Maimaris J, Jenkins P, Albuquerque AS, Hong Y, Eleftheriou D, et al. Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma. Journal of Clinical Immunology. 2023;43(7):1611-1622. doi:10.1007/s10875-023-01530-7

BibTeX
@article{Minskaia2023,
  author = {Minskaia, Ekaterina and Maimaris, Jesmeen and Jenkins, Persephone and Albuquerque, Adriana S and Hong, Ying and Eleftheriou, Despina and Gilmour, Kimberly C and Grace, Richard and Moreira, Fernando and Grimbacher, Bodo and NIHR Bioresource-Rare Diseases Consortium, NIHR Bioresource-Rare Diseases Consortium and Morris, Emma C and Burns, Siobhan O},
  title = {Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma},
  journal = {Journal of Clinical Immunology},
  year = {2023},
  volume = {43},
  number = {7},
  pages = {1611--1622},
  doi = {10.1007/s10875-023-01530-7}
}
Kostenlos starten →